#raisethebar
This just in: exciting news as we continue to #RaiseTheBar for patients facing unmet needs in mental health. The U.S. Food and Drug Administration (U.S. FDA) has granted Breakthrough Therapy designation to DT120 ODT for the treatment of major depressive disorder (MDD), building on our initial designation in generalized anxiety disorder (GAD). Receiving a second Breakthrough Therapy designation marks a huge leap forward and fuels our momentum toward a potential new generation of therapeutics for patients living with mental health disorders. Read the full announcement here: #MentalHealth #DefiniumTherapeutics #Psychedelics #MDD #Depression #BeyondBetter #HealthcareInnovation
Definium Therapeutics13,726 次观看 • 1 个月前
